Table 2.
Cytotoxicity of compounds 1, 2, and 3a–i toward various human cancer cell lines.
| Comp. | IC50 (μg/mL) | |||||||
|---|---|---|---|---|---|---|---|---|
| HepG2 | HL-60 | KB | LLC | LNCaP | LU-1 | MCF7 | SW480 | |
| 1 | >100 | >100 | >100 | >100 | >100 | >100 | >100 | >100 |
| 2 | >100 | >100 | >100 | >100 | >100 | >100 | >100 | >100 |
| 3a | >100 | 82.2 ± 4.5 | 44.1 ± 3.6 | 87.4 ± 6.3 | 77.4 ± 5.8 | 52.9 ± 3.4 | 66.0 ± 2.7 | 71.4 ± 3.6 |
| 3b | 86.3 ± 6.4 | 75.3 ± 3.9 | 84.6 ± 4.2 | >100 | 81.6 ± 6.3 | >100 | 32.8 ± 1.4 | 90.1 ± 4.8 |
| 3c | 78.4 ± 5.8 | 92.3 ± 5.2 | 74.1 ± 5.1 | 90.1 ± 7.7 | 84.2 ± 4.1 | 65.5 ± 4.1 | 52.7 ± 3.6 | 85.4 ± 7.4 |
| 3d | 94.5 ± 6.3 | 74.6 ± 4.6 | 90.2 ± 2.4 | >100 | 92.4 ± 5.7 | 59.0 ± 4.3 | 88.4 ± 7.4 | 84.3 ± 6.2 |
| 3e | 81.4 ± 7.4 | 94.8 ± 6.8 | >100 | 90.2 ± 4.9 | >100 | >100 | >100 | 87.6 ± 4.8 |
| 3f | 78.4 ± 3.4 | 87.6 ± 6.7 | >100 | >100 | 91.6 ± 7.6 | >100 | 65.9 ± 4.7 | 81.3 ± 5.6 |
| 3g | 88.4 ± 6.7 | 84.6 ± 5.4 | >100 | 90.8 ± 5.2 | >100 | >100 | >100 | 90.8 ± 6.4 |
| 3h | 91.3 ± 8.2 | 94.2 ± 7.1 | 88.4 ± 3.5 | 87.4 ± 6.4 | 81.9 ± 4.3 | 85.6 ± 5.6 | >100 | 85.7 ± 3.2 |
| 3i | >100 | 84.3 ± 4.2 | 90.2 ± 2.7 | 92.8 ± 6.4 | 85.1 ± 6.1 | >100 | 80.9 ± 6.9 | 92.5 ± 4.1 |
| Ellipticine | 1.45 ± 0.08 | 0.56 ± 0.04 | 0.43 ± 0.05 | 0.98 ± 0.04 | 0.86 ± 0.06 | 1.29 ± 0.11 | 0.49 ± 0.04 | 0.62 ± 0.05 |